文献速递胸部肿瘤

2020年全球肺癌组织学亚型发病率的地区差异:一项基于人群的研究

Global variations in lung cancer incidence by histological subtype in 2020: a population-based study.
PubMed 文献 · Lancet Oncol · 2023-10-11

该研究基于国际癌症登记数据与GLOBOCAN 2020估计,量化了185个国家四种主要肺癌亚型的全球发病负担。2020年全球肺癌新发约2 206 771例,腺癌已成为最常见的亚型,男性腺癌发病率在150个国家超过鳞状细胞癌,女性则在全部185个国家均超过鳞状细胞癌。

要点

  • 2020年全球肺癌新发2 206 771例,男性1 435 943例,女性770 828例。
  • 男性腺癌占39%、鳞癌25%、小细胞癌11%、大细胞癌8%。
  • 女性腺癌占57%、鳞癌12%、小细胞癌9%、大细胞癌6%。

核心结论

  • 腺癌已成为2020年全球最常见的肺癌亚型,男性腺癌发病率在多数国家超过鳞状细胞癌,女性在全部国家均超过鳞状细胞癌。
  • 研究结果为全球肺癌负担提供了新认识,有助于各世界区域制定针对性的国家预防措施。

研究设计与样本

  • 基于人群的研究,使用《五大洲癌症发病率》第十一卷和非洲癌症登记网络数据,评估185个国家和地区肺癌四种主要亚型(腺癌、鳞状细胞癌、小细胞癌、大细胞癌)的占比,并应用于GLOBOCAN 2020的肺癌发病估计。
  • 未明确形态学分类的病例被重新分配至指定亚型,年龄标化发病率采用世界标准人口计算。

主要发现

  • 2020年全球肺癌新发估计2 206 771例,其中男性1 435 943例,女性770 828例。
  • 男性肺癌病例中腺癌560 108例(39%)、鳞状细胞癌351 807例(25%)、小细胞癌163 862例(11%)、大细胞癌115 322例(8%);女性中腺癌440 510例(57%)、鳞状细胞癌91 070例(12%)、小细胞癌68 224例(9%)、大细胞癌49 246例(6%)。
  • 全球年龄标化发病率(每10万人年)男性腺癌12.4、鳞状细胞癌7.7、小细胞癌3.6、大细胞癌2.6;女性腺癌8.3、鳞状细胞癌1.6、小细胞癌1.3、大细胞癌0.9。
  • 男性腺癌发病率在185个国家中的150个国家超过鳞状细胞癌,女性在全部185个国家均超过鳞状细胞癌。
  • 男性各亚型年龄标化发病率最高的地区分别为:腺癌东亚(23.5)、鳞状细胞癌中欧和东欧(17.5)、小细胞癌西亚(7.2)、大细胞癌东南亚(11.0);女性分别为:腺癌东亚(16.0)、鳞状细胞癌北美(5.4)、小细胞癌北美(4.7)、大细胞癌东南亚(3.4)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Lung cancer is the second most common cancer worldwide, yet the distribution by histological subtype remains unknown. We aimed to quantify the global, regional, and national burden of lung cancer incidence for the four main subtypes in 185 countries and territories. METHODS: In this population-based study, we used data from Cancer Incidence in Five Continents Volume XI and the African Cancer Registry Network to assess the proportions of adenocarcinoma, squamous cell carcinoma, small-cell carcinoma, and large-cell carcinoma among all lung cancers by country, sex, and age group and subsequently applied these data to corresponding national (GLOBOCAN) estimates of lung cancer incidence in 2020. Unspecified morphologies were reallocated to specified subtypes. Age-standardised incidence rates were calculated using the world standard population to compare subtype risks worldwide, adjusted for differences in age composition between populations by country. FINDINGS: In 2020, there were an estimated 2 206 771 new cases of lung cancer, with 1 435 943 in males and 770 828 in females worldwide. In males, 560 108 (39%) of all lung cancer cases were adenocarcinoma, 351 807 (25%) were squamous cell carcinoma, 163 862 (11%) were small-cell carcinoma, and 115 322 (8%) were large-cell carcinoma cases. In females, 440 510 (57%) of all lung cancer cases were adenocarcinoma, 91 070 (12%) were squamous cell carcinoma, 68 224 (9%) were small-cell carcinoma, and 49 246 (6%) were large-cell carcinoma cases. Age-standardised incidence rates for adenocarcinoma, squamous cell carcinoma, small-cell carcinoma, and large-cell carcinoma, respectively, were estimated to be 12·4, 7·7, 3·6, and 2·6 per 100 000 person-years in males and 8·3, 1·6, 1·3, and 0·9 per 100 000 person-years in females worldwide. The incidence rates of adenocarcinoma exceeded those of squamous cell carcinoma in 150 of 185 countries in males and in all 185 countries in females. The highest age-standardised incidence rates per 100 000 person-years for adenocarcinoma, squamous cell carcinoma, small-cell carcinoma, and large-cell carcinoma, respectively, for males occurred in eastern Asia (23·5), central and eastern Europe (17·5), western Asia (7·2), and south-eastern Asia (11·0); and for females occurred in eastern Asia (16·0), northern America (5·4), northern America (4·7), and south-eastern Asia (3·4). The incidence of each subtype showed a clear gradient according to the Human Development Index for male and female individuals, with increased rates in high and very high Human Development Index countries. INTERPRETATION: Adenocarcinoma has become the most common subtype of lung cancer globally in 2020, with incidence rates in males exceeding those of squamous cell carcinoma in most countries, and in females in all countries. Our findings provide new insights into the nature of the global lung cancer burden and facilitates tailored national preventive actions within each world region. FUNDING: None.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Zhang Y, Vaccarella S, Morgan E, et al. Global variations in lung cancer incidence by histological subtype in 2020: a population-based study. Lancet Oncol. 2023. PMID: 37837979. doi:10.1016/S1470-2045(23)00444-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。